Baxter Launches the HEMOPATCH Sealing Hemostat
In a groundbreaking announcement made on May 20, 2025, Baxter International Inc. revealed the launch of the HEMOPATCH Sealing Hemostat, a state-of-the-art collagen pad designed for effective hemostasis and sealing during both open surgeries and minimally invasive surgical procedures (MIS). With its approval for use at room temperature, this innovative product highlights Baxter's commitment to advancing surgical technologies and improving patient outcomes.
Key Features of the HEMOPATCH Sealing Hemostat
According to Steve Wallace, President of Advanced Surgery at Baxter, the introduction of a room-temperature variant of the HEMOPATCH Sealing Hemostat signifies a considerable milestone in tissue management innovations. This new product maintains the convenience of storage without the need for refrigeration, alongside an impressive shelf life of three years. This makes it particularly useful for healthcare facilities looking to optimize inventory management while ensuring that they have essential products readily available for surgical procedures.
The performance of the HEMOPATCH involves the synergy of two components, creating rapid and lasting hemostasis by effectively sealing the bleeding surface. The white, tissue-facing side of the patch is coated with a thin layer of NHS-PEG. Upon contact with blood or bodily fluids, this compound transforms into a hydrogel, enhancing adhesion properties and facilitating a secure seal on the tissue surface. The collagen present in the Hemopatch promotes platelet aggregation, leading to an effective clot formation within mere minutes.
Clinical Benefits and Efficacy
Preclinical studies conducted on the HEMOPATCH demonstrate its significant clinical advantage as it not only stops bleeding but also prevents future leaks, making it an ideal choice for surgeons handling complex procedures. Most notably, the device allows for effective hemostasis within two minutes, providing surgeons with a reliable solution to manage bleeding efficiently during operations. Furthermore, the patch is expected to be absorbed and replaced by host tissue within approximately six to eight weeks, with minimal tissue reaction observed, thus supporting a smoother recovery process for patients.
Usage and Safety Information
The HEMOPATCH Sealing Hemostat is classified as a Class III device under the medical regulations, ensuring that it meets stringent safety and efficacy standards. It is important to state that this device is intended solely for healthcare professionals and should not be interpreted as medical advice. Healthcare providers must assess the suitability of the HEMOPATCH for each specific surgical scenario while remaining abreast of the latest clinical data regarding its use.
To obtain detailed information about the indications, important safety risks, and other relevant data, professionals can visit Baxter’s official product page at
Baxter Advanced Surgery.
Conclusion
With the launch of the HEMOPATCH Sealing Hemostat, Baxter reinforces its position as a leader in advanced surgical solutions. This innovative product not only complements the existing portfolio of surgical aids but also sets a new standard for hemostasis in both traditional and minimally invasive procedures. As healthcare professionals seek to enhance surgical outcomes and improve patient care, devices like the HEMOPATCH stand out as indispensable tools to meet these objectives.